Search

New York University has been granted a patent for a paper capillary lateral flow fluid filter that addresses the issue of clean water scarcity, particularly in poor and developing countries. The filtration system uses multiple filters to remove contaminants from water without the need for chemicals or radiation. It is cost-effective, adjustable, and suitable for point-of-use water filtration with minimal maintenance and consumables. The patent describes a system that uses various filters and can be used in a range of applications, including water purification, food processing, and the oil and gas industry. The patent also includes a method for fluid filtration using the described system. [Extracted from the article]

A patent application has been submitted by inventors Sean Farmer and Andrew R. Lefkowitz, focusing on improving the environmental impact of printing and dyeing processes. The application proposes using "green" alternatives to traditional chemicals in inks and processes to reduce water and chemical usage and wastewater pollution. The application suggests using biological amphiphilic molecules as substitutes for chemical surfactants, which can serve various functions such as detergents, lubricants, and emulsifiers. These molecules can enhance the performance of inks, dyes, solvents, and equipment maintenance. The patent application describes compositions and methods for improving the environmental impact of printing and dyeing processes, including the use of biological amphiphilic molecules as adjuvants or active ingredients in delivering and fixing colorants to surfaces. These methods can be applied to various materials such as textiles, paper, polymers, wood, glass, ceramics, and packaging materials. The use of biological amphiphilic molecules can reduce water and chemical usage, water pollution, and improve the performance of printing and dyeing processes. Additionally, the compositions can be used for de-inking surfaces and cleaning equipment. [Extracted from the article]

A patent has been issued for a device and method to assess hand flexion tone. The device, called the Isometric Force Pillow (IFP), measures static flexion force from the fingers to provide a quantitative measure of involuntary finger grip due to spastic hypertonia. The IFP can be used to evaluate hand flexion caused by muscle tone, hypertonia, spastic hypertonia, the flexion synergy, or contractures. It consists of an inflatable pillow that is wrapped around the hand and connected to an air pressure sensor, which converts the air pressure changes into therapeutic meaningful values. The device could be used to assess the effectiveness of interventions for relieving hypertonia. [Extracted from the article]

CellOrigin Biotechnology has announced the treatment of the first patient in China with their CAR-macrophage therapy product (CAR-M) SY001. This marks the first investigator-initiated clinical study of CAR-M cell therapy in China. The treatment was well tolerated with no dose-limiting toxicity observed, and the company expects that this innovative product will prove its safety and effectiveness in clinical trials, offering new hope for the treatment of solid tumors. CellOrigin has also collaborated with Zhejiang University on research papers exploring the development of second-generation CAR-iMAC and targeted glycan degradation for solid tumors. They are conducting further pre-clinical and clinical studies to provide safe and effective treatment choices for patients. [Extracted from the article]

A patent application has been published for a disposable cartridge designed for drug delivery devices. The cartridge features a flexible bag to hold liquid medication and a socket with a fluid channel that extends into the bag's opening. The bag is sealed between the socket and a housing, eliminating the need for adhesives or heat. The invention aims to provide a better seal and prevent obstructions in the fluid channel, improving the quality of the medication and simplifying the manufacturing process. [Extracted from the article]

Mission Therapeutics has begun a Phase I clinical trial for MTX325, a potential disease-modifying treatment for Parkinson's Disease (PD). The trial aims to evaluate the safety, tolerability, pharmacokinetics, and brain penetration of MTX325 in healthy volunteers and PD patients. The treatment targets USP30, a deubiquitylating enzyme that inhibits mitophagy, a process involved in removing dysfunctional mitochondria. The trial follows preclinical research that provided evidence supporting the potential of MTX325 to modify the course of PD. [Extracted from the article]

A patent has been issued for a smart self-activating wearable device that automatically injects medicines. The device is designed to treat acute medical conditions that require immediate treatment, such as drug overdose or anaphylactic shock. It overcomes the limitations of current automatic drug injection systems by being wearable, unobtrusive, and requiring no human intervention. The device includes an enclosure, an injection cylinder, an injection piston, hypodermic needles, and a valve member to control the flow of the injected fluid. The patent was filed by Innovative Health Strategies LLC and published online on March 5, 2024. [Extracted from the article]

Q32 Bio, a biotechnology company, has published preclinical data in Molecular Therapy that supports the therapeutic potential of their tissue-targeted complement inhibitor, ADX-097. The data demonstrates the effectiveness of ADX-097 in reducing glomerular injury without affecting circulating complement. Q32 Bio has completed a Phase 1 clinical trial of ADX-097 and plans to initiate Phase 2 trials in renal disease and ANCA-Associated Vasculitis. The company's approach to tissue-targeted complement inhibition shows promise in treating complement-mediated diseases. [Extracted from the article]

Edison Liu, MD, President and CEO Emeritus of the Jackson Laboratory, has joined Verseon's scientific advisory board. Dr. Liu is an internationally recognized expert in cancer biology, functional genomics, and translational medicine. He has held various leadership positions in the field, including serving as the founding executive director of the Genome Institute of Singapore and president of the Human Genome Organization. Dr. Liu's expertise will be valuable in advancing Verseon's technology for drug development, particularly in the field of cancer research. [Extracted from the article]

A patent application titled "Method Of Using Reinforced Flexible Circuits With Multiple Sensors To Optimize Performance Of Radio Frequency Devices" has been published online by the US Patent and Trademark Office. The application, filed by inventors Jason L. Harris, Frederick E. Shelton IV, and David C. Yates, relates to surgical systems, surgical instruments, and flexible circuits. The invention involves a method implemented by a surgical instrument that utilizes a flexible circuit with multiple sensors to optimize the performance of a radio frequency (RF) device. The method includes contacting tissue with therapeutic and sensing electrodes, sensing signals from the sensing electrodes, and controlling RF energy delivered to the therapeutic electrode based on the sensed signals. [Extracted from the article]